TRCT
ENSC icon

Tower Research Capital (TRC)’s Ensysce Biosciences ENSC Stock Holding History

Tower Research Capital (TRC)’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.28K Buy
6,094
+775
+15% +$491 ﹤0.01% 4338
2025
Q4 		$4.89K Buy
5,319
+3,971
+295% +$7.37K ﹤0.01% 4169
2025
Q3 		$3.19K Sell
1,348
-21
-2% -$45 ﹤0.01% 4534
2025
Q2 		$3.05K Buy
1,369
+928
+210% +$2.13K ﹤0.01% 4559
2025
Q1 		$1.13K Buy
441
+3
+0.7% +$17 ﹤0.01% 4770
2024
Q4 		$3.56K Buy
438
+8
+2% +$55 ﹤0.01% 4638
2024
Q3 		$1.55K Sell
430
-120
-22% -$728 ﹤0.01% 5138
2024
Q2 		$4.19K Buy
550
+6
+1% +$55 ﹤0.01% 4808
2024
Q1 		$6.45K Buy
544
+124
+30% +$1.97K ﹤0.01% 4367
2023
Q4 		$6.68K Buy
420
+158
+60% +$2.54K ﹤0.01% 4710
2023
Q3 		$5.42K Buy
262
+2
+0.8% +$57 ﹤0.01% 4721
2023
Q2 		$7.02K Buy
260
+216
+491% +$9.77K ﹤0.01% 4632
2023
Q1 		$3K Buy
44
+40
+1,000% +$4.59K ﹤0.01% 5185
2022
Q4 		$1K Hold
4
– – ﹤0.01% 5580
2022
Q3 		$3K Buy
4
+3
+300% +$4.89K ﹤0.01% 5383
2022
Q2 		$3K Sell
1
-2
-67% -$5.6K ﹤0.01% 5367
2022
Q1 		$12K Sell
3
-6
-67% -$39.7K ﹤0.01% 4053
2021
Q4 		$153K Buy
9
+6
+200% +$56.5K ﹤0.01% 1959
2021
Q3 		$32K Buy
+3
New +$58.6K ﹤0.01% 3305

Other funds holding ENSC

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TIAM2
Tru Independence Asset Management 2 Portland, Oregon $163M AUM 18.06% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tower Research Capital (TRC)'s ENSC Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Ensysce Biosciences (ENSC) stake by 15% in Q1 2026, buying an estimated $491 and bringing the position to 6,094 shares worth $3.28K. The position accounts for ﹤0.01% of the portfolio, ranked #4338.

Tower Research Capital (TRC) first reported a position in ENSC in Q3 2021 and has held it in 19 quarters since. The position peaked at $153K in Q4 2021. 15 funds tracked by Wall St. Rank hold ENSC as of Q1 2026.

  • Tower Research Capital (TRC) held 6,094 shares of Ensysce Biosciences worth $3.28K as of Q1 2026.
  • Tower Research Capital (TRC) bought 775 Ensysce Biosciences shares in Q1 2026, an estimated $491.
  • Ensysce Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4338 holding.
  • Tower Research Capital (TRC) first reported a position in Ensysce Biosciences in Q3 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Ensysce Biosciences position peaked at $153K in Q4 2021.
  • 15 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.